Sorafenib and Radioembolization With Sir-Spheres for the Treatment of Metastatic Ocular Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions; Biomarker
- 22 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 22 Aug 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2017.
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.